More than 6.5 million people in the United States have Alzheimer’s disease. The irreversible disease destroys memory, thinking skills, and, eventually, the ability to carry out simple tasks.

Neurologists at CAMC will soon have a new tool to help treat Alzheimer’s. On Jan. 6, the Food and Drug Administration Jan. 6, granted accelerated approval for the Alzheimer’s drug, lecanemab.